HER2-targeted therapy: an emerging strategy in advanced colorectal cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017 Apr;66(4):683–691.
   PubMed Web of Science ®Google Scholar
• Chand M, Keller DS, Mirnezami R, et al. Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data. World J Gastrointest Oncol. 2018 Jul 15;10(7):145–158.
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.
   PubMed Web of Science ®Google Scholar
• De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–762.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–137.
   PubMed Web of Science ®Google Scholar
• Song Z, Deng Y, Zhuang K, et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol. 2014;7(7):4454–4460.
   PubMed Web of Science ®Google Scholar
• Muzny DM, Bainbridge MN, Chang K. et al. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012. 487. 7407. 330–337.
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene. 2003;22(42):6570–6578.
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–278.
   PubMed Web of Science ®Google Scholar
• Calhoun BC, Collins LC. Predictive markers in breast cancer: an update on ER and HER2 testing and reporting. Semin Diagn Pathol. 2015;32(5):362–369.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Breast. 2017;31:244–259.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Verheij M, Allum W, et al. ESMO guidelines committee. Ann gastric cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Oncol. 2016 Sep;27(suppl 5):v38–v49.
   Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697.
   PubMed Web of Science ®Google Scholar
• Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19:554–568.
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;17(8):895–904.
   Google Scholar
• Herreros-Villanueva M, Rodrigo M, Claver M, et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep. 2011;38:1315–1320.
   PubMed Web of Science ®Google Scholar
• Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018 May 1;29(5):1108–1119.
   PubMed Web of Science ®Google Scholar
• Farzand S, Siddique T, Saba K, et al. Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system. World J Gastroenterol. 2014;20:5889–5896.
   PubMed Web of Science ®Google Scholar
• Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562 570.
   Web of Science ®Google Scholar
• Laurent-Puig P, Balogoun R, Cayre A, et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol 2016;27;(6):149-206.  abstr 459O.
   PubMed Web of Science ®Google Scholar
• Osako T, Miyahara M, Uchino S, et al. Immunohistochemical study of cerbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;55(6):548–555.
   Google Scholar
• Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103–1113.
   PubMed Web of Science ®Google Scholar
• Kruszewski WJ, Rzepko R, Ciesielski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207–212.
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and HER-2/neu in colorectal adenocarcinomas. Cancer J. 2006;12(3):229–236.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Vernieri C, Siravegna G, et al. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23(10):2414–2422.
   PubMed Web of Science ®Google Scholar
• Sun S-J, Lin Q, Sun Q, et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J Can Res Ther. 2016;12(1):323–333.
   PubMed Web of Science ®Google Scholar
• Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–1984.
   PubMed Web of Science ®Google Scholar
• Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33:1809–1824.
   PubMed Web of Science ®Google Scholar
• Misale S, Di Nicolantonio F, Sartore-Bianchi A, et al. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4:1269–1280.
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–1174.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3: 99ra86
   PubMed Web of Science ®Google Scholar
• Raghav KPS, Overman MJ, Yu R, et al. HER2 amplification as a negative predictor biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol 2016;34:suppl 15; abstr 3517.
   Google Scholar
• Martin V, Landi L, Molinari F, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013;108(3):668–675.
   PubMed Web of Science ®Google Scholar
• Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1:508–523.
   PubMed Web of Science ®Google Scholar
• Leto SM, Sassi F, Catalano I, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res. 2015;21(24):5519–5531.
   PubMed Web of Science ®Google Scholar
• Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5(8):832–841.
   PubMed Web of Science ®Google Scholar
• Clark JW, Hollis D, Mayer R, et al. Phase II trial of 5-fluorouracil (5- FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Onkologie. 2003;26(Suppl 3):13–46.
   PubMedGoogle Scholar
• Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. Cancer Invest. 2004;22:858–865.
   PubMed Web of Science ®Google Scholar
• Greally M, Kelly CM, Cercek A. HER2: an emerging target in colorectal cancer. Curr Probl Cancer. 2018; 17:30139-3.
   PubMed Web of Science ®Google Scholar
• Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–746.
   PubMed Web of Science ®Google Scholar
• Deeken JF, Wang H, Subramaniam D, et al. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies. Cancer. 2015;121(10):1645–1653.
   PubMed Web of Science ®Google Scholar
• Siena S, Sartore-Bianchi A, Trusolino L, et al. Final results of the HERACLES trial in HER2-amplified colorectal cancer. 2017 AACR Annual Meeting. Abstract CT005. Presented April 2, 2017.
   Google Scholar
• Bardelli A, Siravegna G, Sartore B, et al. Plasma HER2 (ERBB2) copy number to predict response to HER2-targeted therapy in metastatic colorectal cancer. 2018 ASCO Annual Meeting. J Clin Oncol 2018;36:suppl; abstr 3506.
   Google Scholar
• Hainsworth JD, Meric-Bernstam F, Swanton C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from mypathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018 Feb 20;36(6):536–542.
   PubMed Web of Science ®Google Scholar
• Trusolino L, Bertotti A, Lonardi S, et al. Pertuzumab and trastuzumab-emtansine in HER2-positive colorectal cancer: the HERACLES B trial. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research. New Orleans, LA. Philadelphia (PA): Apr 16-20 2016. AACR; Cancer Res 2016; 76(14Suppl):Abstract nr CT082; DOI:10.1158/1538-7445.AM2016-CT082.
   Google Scholar
• English DP, Bellone S, Schwab CL, et al. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Med. 2014;5:1256–1265.
   Google Scholar
• Schmoll HJ, Arnold D, de Gramont A, et al. MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approach. J Cancer Res Clin Oncol. 2018 Jun;144(6):1197–1204.
   PubMed Web of Science ®Google Scholar
• Moulder SL, Borges VF, Baetz T. Phase i study of ont-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ metastatic breast cancer (MBC). Clin Cancer Res. 2017;23(14):3529–3536.
   PubMed Web of Science ®Google Scholar
• Strickler JH, Niedzwiecki D, Zemla T, et al. A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER). J Clin Oncol. 2017 suppl; abstr TPS3624
   PubMedGoogle Scholar
• Tiwari SR, Mishra P, Abraham J. A novel HER2-targeted tyrosine kinase inhibitor. Clin Breast Cancer. 2016;16(5):344–348.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189–194.
   PubMed Web of Science ®Google Scholar
• Doi T, Shitara K, Yochi N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18(11):1512–1522.
   PubMed Web of Science ®Google Scholar
• Mu Z, Klinowska T, Dong X, et al. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models. J Exp Clin Cancer Res. 2014;33:47.
   PubMed Web of Science ®Google Scholar
• Tjulandin S, Moiseyenko V, Semiglazov V, et al. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Invest New Drugs. 2014;32(1):145–153.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Douillard JY, Ducreux M, et al. Targeted therapy in metastatic colorectal cancer an example of personalized medicine in action. Cancer Treat Rev. 2013;39(6):592–601.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Van der Velden DL, Opdam FL, Voest EE. TAS-102 for treatment of advanced colorectal cancers that are no longer responding to other therapies. Clin Cancer Res. 2016;22(12):2835–2839.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 Jun 25;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182–1191.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in dna mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Mar 10;36(8):773–779.
   PubMed Web of Science ®Google Scholar